Risk of systemic vasculitis following mRNA COVID-19 vaccination: a pharmacovigilance study.

Mettler, Camille; Terrier, Benjamin; Treluyer, Jean-Marc; Chouchana, Laurent

Mettler, Camille; Terrier, Benjamin; Treluyer, Jean-Marc; Chouchana, Laurent.

Mettler C; Assistance Publique-Hôpitaux de Paris, Département de Pharmacologie, Centre Régional de Pharmacovigilance, Hôpital Cochin.
Terrier B; Assistance Publique-Hôpitaux de Paris, Département de Médecine Interne, Centre de Référence National pour les maladies auto-immunes systémiques rares, Hôpital Cochin.
Treluyer JM; Assistance Publique-Hôpitaux de Paris, Département de Médecine Interne, Centre de Référence National pour les maladies auto-immunes systémiques rares, Hôpital Cochin.
Chouchana L; Université Paris, Paris, France.

Rheumatology (Oxford) ; 61(12): e363-e365, 2022 Nov 28.

Article in English | MEDLINE | ID: covidwho-1873995

Subject(s)

2019-nCoV Vaccine mRNA-1273; Systemic Vasculitis; Vaccination; Humans; COVID-19/prevention & control; Pharmacovigilance; Systemic Vasculitis/epidemiology; Vaccination/adverse effects; 2019-nCoV Vaccine mRNA-1273/adverse effects

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Vaccination / Systemic Vasculitis / 2019-nCoV Vaccine mRNA-1273 Type of study: Observational study / Prognostic study Topics: Vaccines Limits: Humans Language: English Journal: Rheumatology (Oxford) Journal subject: Rheumatology Year: 2022 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google